NEW YORK (awp international) – The US stock exchanges have picked up on their weak previous week to kick off Monday trading. Analyst Craig Erlam from broker Oanda identified several negative factors with the effects of the Corona variant Omikron, the monetary policy tightening plans of the major central banks and the impending failure of US President Joe Biden’s social and climate plans. The US bank Goldman Sachs even lowered its growth forecast for the US economy after the Democratic Senator Joe Manchin announced on Sunday that he would not agree to a billion dollar social and climate package.
In the first hour of trading after the stock market launch in the Christmas week, the leading index Dow Jones Industrial reacted to this mixed situation with a discount of 1.74 percent to 34,751 points. Financial stocks made the new economic worries to create: The papers of Goldman Sachs, American Express and JPMorgan fell by up to 3.1 percent.
The market-wide S&P 500 slipped 1.62 percent to 4546 points. For the technology-heavy Nasdaq 100, which came off quite lightly on Friday compared to the standard values, it was now 1.39 percent to 15,581 points.
The SAP competitor Oracle has now confirmed the takeover of the health software specialist Cerner. Oracle pays $ 28.3 billion, or $ 95 per share, for this. The Cerner shares, which had already reacted on Friday with a plus of around 13 percent to a press report on the subject, now rose by 0.8 percent, Oracle fell by 2.9 percent.
Papers from vaccine manufacturers were once again the focus. The recently strong Novavax titles turned into the red with 1.6 percent. The fact that the EU Medicines Agency EMA paved the way for approval of its vaccine did not have a positive effect at first. After approval by the EU Commission, the Novavax vaccine will be the fifth corona vaccine in the EU. The responsible commission of experts issued the recommendation after an extraordinary meeting.
The shares in Biontech listed in New York rose by a little more than one percent. The Mainz corona vaccine pioneer and its US partner Pfizer are supplying the EU with an additional 20 million doses of their joint vaccine for the first three months of 2022 because of Omikron. This brings the total number of expected deliveries from Biontech / Pfizer to the EU in the first quarter to 215 million.
A similar agreement had been concluded with the manufacturer Moderna, the EU Commission said. Its shares also benefited with a plus of a good one percent from the fact that a booster with the Moderna vaccine significantly increases the body’s immune defense against Omikron, according to the manufacturer.
The price of the New York-listed papers of the biotech company Beigene benefited from an option, cooperation and license agreement concluded with Novartis for the drug candidate Ociperlimab with plus 0.8 percent./ajx/men
– .
